Effects of digoxin on cell cycle, apoptosis and NF-κB pathway in Burkitt’s lymphoma cells and animal model

References

• Molyneux EM, Rochford R, Griffin B, et al. Burkitt's lymphoma. The Lancet. 2012;379:1234–1244.
   PubMed Web of Science ®Google Scholar
• Perkins AS, Friedberg JW. Burkitt lymphoma in adults. ASH Educ Prog Book. 2008;2008:341–348.
   Google Scholar
• Nguyen AN, Jansson K, Fau-Sanchez G, et al. Ouabain activates the Na-K-ATPase signalosome to induce autosomal dominant polycystic kidney disease cell proliferation. Am J Physiol Renal Physiol. 2011;301:F897–F906.
   PubMed Web of Science ®Google Scholar
• Schatzmann H, Räss B. Inhibition of the active Na–K-transport and Na–K-activated membrane ATP-ase of erythrocyte stroma by ouabain. Helv Physiol Pharmacol Acta. 1965;65:C47–C49.
   PubMedGoogle Scholar
• Winnicka K, Bielawski K, Bielawska A, et al. Apoptosis-mediated cytotoxicity of ouabain, digoxin and proscillaridin A in the estrogen independent MDA-MB-231 breast cancer cells. Arch Pharm Res. 2007;30:1216–1224.
   PubMed Web of Science ®Google Scholar
• Bielawski K, Winnicka K, Bielawska A. Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol Pharm Bull. 2006;29:1493–1497.
   PubMed Web of Science ®Google Scholar
• Platz EA, Yegnasubramanian S, Liu JO, et al. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov. 2011;1:68–77.
   PubMed Web of Science ®Google Scholar
• Lin S-Y, Chang H-H, Lai Y-H, et al. Digoxin suppresses tumor malignancy through inhibiting multiple Src-related signaling pathways in non-small cell lung cancer. PLoS One. 2015;10:e0123305. doi: 10.1371/journal.pone.0123305.
   PubMed Web of Science ®Google Scholar
• Boursi B, Haynes K, Mamtani R, et al. Digoxin use and the risk for colorectal cancer. Pharmacoepidemiol Drug Saf. 2014;23:1147–1153.
   PubMed Web of Science ®Google Scholar
• Biggar RJ, Wohlfahrt J, Melbye M. Digoxin use and the risk of cancers of the corpus uteri, ovary and cervix. Int J Cancer. 2012;131:716–721.
   PubMed Web of Science ®Google Scholar
• Ihenetu K, Qazzaz HM, Crespo F, et al. Digoxin-like immunoreactive factors induce apoptosis in human acute T-cell lymphoblastic leukemia. Clin Chem. 2007;53:1315–1322.
   PubMed Web of Science ®Google Scholar
• Lu G-Y, Liu S-T, Huang S-M, et al. Multiple effects of digoxin on subsets of cancer-associated genes through the alternative splicing pathway. Biochimie. 2014;106:131–139.
   PubMed Web of Science ®Google Scholar
• Leu W-J, Chang H-S, Chan S-H, et al. Reevesioside A, a cardenolide glycoside, induces anticancer activity against human hormone-refractory prostate cancers through suppression of c-myc expression and induction of G1 arrest of the cell cycle. PLoS One. 2014;9:e87323.
   PubMed Web of Science ®Google Scholar
• Kirmizibekmez H, Masullo M, Festa M, et al. Steroidal glycosides with antiproliferative activities from Digitalis trojana. Phytother Res. 2014;28:534–538.
   PubMed Web of Science ®Google Scholar
• Duran M, Chosseler M, Pressley T. Regulation of Na, K-pump-mediated transport by prolactin in cultured human prostate epithelial cells. Cell Mol Biol (Noisy-Le-Grand, France). 2004;50:809–814.
   PubMed Web of Science ®Google Scholar
• Schoner W. Sodium pump and steroid hormone receptor. Na(+)/K(+)-ATPase. Eur J Biochem. 2002;269:2423.
   PubMedGoogle Scholar
• Mijatovic T, Mathieu V, Gaussin J-F, et al. Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers. Neoplasia. 2006;8:402–412.
   PubMed Web of Science ®Google Scholar
• Mijatovic T, De Beeck AO, Van Quaquebeke E, et al. The cardenolide UNBS1450 is able to deactivate nuclear factor κB-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol Cancer Ther. 2006;5:391–399.
   PubMed Web of Science ®Google Scholar
• Guo J-L, Zheng S-J, Li Y-N, et al. Toxicarioside A inhibits SGC-7901 proliferation, migration and invasion via NF-κB/bFGF signaling. World J Gastroenterol. 2012;18:1602–1609.
   PubMed Web of Science ®Google Scholar
• Xie CM, Liu X, Fau-Yu S, et al. Cardiac glycosides block cancer growth through HIF-1α- and NF-κB-mediated Plk1. Carcinogenesis. 2013;34:1870–1880.
   PubMed Web of Science ®Google Scholar
• Kumar A, De T, Mishra A, et al. Oleandrin: a cardiac glycosides with potent cytotoxicity. Pharmacogn Rev. 2013;7:131.
   PubMedGoogle Scholar
• Ren Y-P, Zhang M-J, Zhang T, et al. Dual effects of ouabain on the regulation of proliferation and apoptosis in human umbilical vein endothelial cells: involvement of Na+-K+-ATPase α-subunits and NF-κB. Int J Clin Exp Med. 2014;7:1214.
   PubMed Web of Science ®Google Scholar
• Kanda K, Hu H-M, Zhang L, et al. NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer. J Biol Chem. 2000;275:32338–32346.
   PubMed Web of Science ®Google Scholar
• Samatiwat P, Prawan A, Senggunprai L, et al. Nrf2 inhibition sensitizes cholangiocarcinoma cells to cytotoxic and antiproliferative activities of chemotherapeutic agents. Tumour Biol. 2016;37:11495–11507.
   PubMed Web of Science ®Google Scholar
• Karimian H, Moghadamtousi SZ, Fadaeinasab M, et al. Ferulago angulata activates intrinsic pathway of apoptosis in MCF-7 cells associated with G1 cell cycle arrest via involvement of p21/p27. Drug Des Dev Ther. 2014;8:1481.
   PubMed Web of Science ®Google Scholar
• Sun H, Lin DC, Guo X, et al. Inhibition of IRE1alpha-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. Oncotarget. 2016;7:18736–18749.
   PubMed Web of Science ®Google Scholar
• Kometiani P, Liu L, Fau-Askari A, et al. Digitalis-induced signaling by Na+/K+-ATPase in human breast cancer cells. Mol Pharmacol. 2005;67:929–936.
   PubMed Web of Science ®Google Scholar
• De Jong J, Van Diest P, Michalides R, et al. Concerted overexpression of the genes encoding p21 and cyclin D1 is associated with growth inhibition and differentiation in various carcinomas. Mol Pathol. 1999;52:78.
   PubMedGoogle Scholar
• Santoni-Rugiu E, Falck J, Mailand N, et al. Involvement of Myc activity in a G1/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol. 2000;20:3497–3509.
   PubMed Web of Science ®Google Scholar
• Dang CV, O'Donnell KA, Juopperi T. The great MYC escape in tumorigenesis. Cancer Cell. 2005;8:177–178.
   PubMed Web of Science ®Google Scholar
• Park SR, Cho H, Fau-Moon KJ, et al. Cytotoxic effects of novel phytosphingosine derivatives, including N,N-dimethylphytosphingosine and N-monomethylphytosphingosine, in human leukemia cell line HL60. Leuk Lymphoma. 2010;51:132–145.
   PubMed Web of Science ®Google Scholar
• Ramirez-Ortega M, Maldonado-Lagunas V, Melendez-Zajgla J, et al. Proliferation and apoptosis of HeLa cells induced by in vitro stimulation with digitalis. Eur J Pharmacol. 2006;534:71–76.
   PubMed Web of Science ®Google Scholar
• Daniel D, Susal C, Fau-Kopp B, et al. Apoptosis-mediated selective killing of malignant cells by cardiac steroids: maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives. Int Immunopharmacol. 2003;3:1791–1801.
   PubMed Web of Science ®Google Scholar
• Alonso E, Cano-Abad MF, Moreno-Ortega AJ, et al. Nanomolar ouabain elicits apoptosis through a direct action on HeLa cell mitochondria. Steroids. 2013;78:1110–1118.
   PubMed Web of Science ®Google Scholar
• Sakai H, Suzuki T, Maeda M, et al. Up-regulation of Na(+),K(+)-ATPase alpha 3-isoform and down-regulation of the alpha1-isoform in human colorectal cancer. FEBS Lett. 2004;563:151–154.
   PubMed Web of Science ®Google Scholar
• Nigim F, Cavanaugh J, Patel AP, et al. Targeting hypoxia-inducible factor 1alpha in a new orthotopic model of glioblastoma recapitulating the hypoxic tumor microenvironment. J Neuropathol Exp Neurol. 2015;74:710–722.
   PubMed Web of Science ®Google Scholar
• Gao C, Li S, Zhao T, et al. SCF, regulated by HIF-1α, promotes pancreatic ductal adenocarcinoma cell progression. PLoS One. 2015;10:e0121338.
   PubMed Web of Science ®Google Scholar
• Morris G, DeNardo SJ, DeNardo GL, et al. Decreased C-MYC and BCL2 expression correlates with methylprednisolone-mediated inhibition of Raji lymphoma growth. Biochem Mol Med. 1997;60:108–115.
   PubMedGoogle Scholar
• Zappasodi R, Cavane A, Iorio MV, et al. Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas. Int J Cancer. 2014;135:2034–2045.
   PubMed Web of Science ®Google Scholar